天眼查App显示,2025-10-14,“Cbl-b抑制剂”正式进入专利的公布阶段。申请人为北京诺诚健华医药科技有限公司,该项医药化学专利涉及癌症等Cbl‑b介导疾病的治疗与预防。据专利信息显示,该杂环类化合物或其可药用的盐在抑制Cbl‑b方面取得突破性进展。发明人为庞育成;陈向阳。本发明涉及作为Cbl‑b抑制剂的杂环类化合物或其可药用的盐。具体而言,本发明涉及一种通式(I)所示的化合物或其可药用...
Source Link天眼查App显示,2025-10-14,“Cbl-b抑制剂”正式进入专利的公布阶段。申请人为北京诺诚健华医药科技有限公司,该项医药化学专利涉及癌症等Cbl‑b介导疾病的治疗与预防。据专利信息显示,该杂环类化合物或其可药用的盐在抑制Cbl‑b方面取得突破性进展。发明人为庞育成;陈向阳。本发明涉及作为Cbl‑b抑制剂的杂环类化合物或其可药用的盐。具体而言,本发明涉及一种通式(I)所示的化合物或其可药用...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.